Related Experiment Video
Updated: Aug 13, 2025
Using 22C3 Anti-PD-L1 Antibody Concentrate on Biopsy and Cytology Samples from Non-small Cell Lung Cancer Patients
Published on: September 25, 2018
PD-L1 and PD-L2 expression in colorectal cancer
Ozgul Zeynep1, Canaz Funda2, Yılmaz Evrim2
1Atatürk Public Hospital, Pathology, Antalya, Turkey.
Context:
The programmed death-1 (PD-1) is an immune checkpoint molecule that suppresses T-cell response. The binding of PD-1 to PD-L1/PD-L2 results cytokine production, and T-cell proliferation are reduced. Tumors expressing PD-L1 and PD-L2 escape from cytotoxic T-cells and are exposed to tumor progression. For this reason, immunotherapy has become a new option in the treatment of cancer.
Aims:
In this study, we examined the PD-L1 and PD-L2 expression in colorectal carcinoma (CRC), and evaluated the relationship between clinicopathological parameters and CD8+ T cells.
Methods And Material:
We evaluated CD8 expression in tumor-infiltrating lymphocytes and surrounding tumor lymphocytes with PD-L1, PD-L2 staining in tumor cells and immune cells formalin-fixed paraffin embedded samples of 124 patient diagnosed with CRC.
Statistical Analysis Used:
Pearson Chi-Square, Fisher Exact Chi-Square, and Pearson Exact Chi-Square analyses were used in the analysis of the cross tables. Survival distributions predicted Kaplan--Meier method and it was evaluated using log-rank statistics.
Results:
In our study, a significant correlation was found between PD-L1 expression and female sex and tumors with medullary morphology. No expression of PD-L2 was observed in tumors containing medullary morphology, and a statistically inverse relationship was observed between PD-L2 and the medullary component. PD-L1 positive tumor-infiltrating lymphocytes were determined to be an important predictor for recurrence-free survival.
Conclusions:
We believe that the evaluation of these parameters may be useful in the selection of patients who will benefit from immunotherapy in CRC cases.
Insights
Programmed death-1 (PD-1) ligands PD-L1 and PD-L2 were analyzed in colorectal cancer. PD-L1 expression correlated with female sex and medullary tumors, predicting recurrence-free survival in immunotherapy candidates.
Area of Science:
- Immunology
- Oncology
- Pathology
Background:
- Programmed death-1 (PD-1) is an immune checkpoint molecule that inhibits T-cell responses.
- Tumors expressing PD-L1/PD-L2 evade cytotoxic T-cells, leading to tumor progression.
- Immunotherapy offers a new treatment avenue for cancer.
Purpose of the Study:
- To investigate PD-L1 and PD-L2 expression in colorectal carcinoma (CRC).
- To assess the relationship between PD-L1/PD-L2 expression, clinicopathological parameters, and CD8+ T cells in CRC.
Main Methods:
- Analysis of PD-L1 and PD-L2 expression in 124 CRC patient samples.
- Evaluation of CD8 expression in tumor-infiltrating and surrounding lymphocytes.
- Statistical analyses including Chi-Square tests, Kaplan-Meier, and log-rank statistics.
Main Results:
- PD-L1 expression showed a significant correlation with female sex and medullary tumor morphology.
- PD-L2 expression was not observed in medullary tumors, with an inverse relationship to the medullary component.
- PD-L1 positive tumor-infiltrating lymphocytes were a significant predictor of recurrence-free survival.
Conclusions:
- PD-L1 and PD-L2 expression patterns are associated with specific clinicopathological features in CRC.
- PD-L1 expression in tumor-infiltrating lymphocytes is a valuable prognostic marker for recurrence-free survival.
- Evaluating these markers may aid in selecting CRC patients who will benefit from immunotherapy.
More Related Videos
10:29Semi-automatic PD-L1 Characterization and Enumeration of Circulating Tumor Cells from Non-small Cell Lung Cancer Patients by Immunofluorescence
Published on: August 14, 2019
09:32Multiplexed Immunofluorescence Analysis and Quantification of Intratumoral PD-1+ Tim-3+ CD8+ T Cells
Published on: February 8, 2018